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A B S T R A C T
Objective: This study aimed to evaluate two cleaning solutions for the chemical decontamination of 
antineoplastic agents on the surfaces of two biosafety cabinets routinely used for chemotherapy prepa-
ration in a hospital pharmacy.
Methods: For almost 1 year (49 weeks), two different solutions were used for the weekly cleaning of 
two biosafety cabinets in a hospital pharmacy’s centralized cytotoxic preparation unit. The solutions 
evaluated were a commercial solution of isopropyl alcohol (IPA) and water (70:30, vol:vol), and a 
detergent solution constituted by 10–2 M of sodium dodecyl sulfate (SDS) with 20% IPA. Seven areas 
in each biosafety cabinet were wiped 14 times throughout the year, before and after the weekly clean-
ing process, according to a validated procedure. Samples were analyzed using a validated method of 
high-performance liquid chromatography coupled to mass spectrometry. The decontamination effi-
cacy of these two solutions was tested for 10 antineoplastic agents: cytarabine, gemcitabine, metho-
trexate, etoposide phosphate, irinotecan, cyclophosphamide, ifosfamide, doxorubicin, epirubicin, and 
vincristine.
Results: Overall decontamination efficacies observed were 82 ± 6% and 49 ± 11% for SDS solution 
and IPA, respectively. Higher contamination levels were distributed on areas frequently touched by the 
pharmacy technicians—such as sleeves and airlock handles—than on scale plates, gravimetric control 
hardware, and work benches. Detected contaminations of cyclophosphamide, ifosfamide, gemcitabine, 
and cytarabine were higher than those of the others agents. SDS solution was almost 20% more efficient 
than IPA on eight of the antineoplastic agents.
Conclusion: Both cleaning solutions were able to reduce contamination levels in the biosafety cabi-
nets. The efficacy of the solution containing an anionic detergent agent (SDS) was shown to be generally 
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higher than that of IPA and, after the SDS cleaning procedure, biosafety cabinets demonstrated accept-
able contamination levels.
K E Y W O R D S :  antineoplastic analysis; cleaning; decontamination; detergents; hospital; occupational 
prevention and control; pharmacy service 
I N T R O D U C T I O N
Antineoplastic agents used in cancer therapy are 
substances that nonspecifically inhibit or stop cell 
development. These molecules are potentially haz-
ardous because they do not distinguish diseased 
cells from healthy ones, creating undesirable side 
effects in patients. Healthcare professionals, such 
as pharmacists, oncology nurses, physicians, and 
technicians, there forerun a real risk of being con-
taminated by antineoplastic agents during their 
daily routines, if they work with these compounds. 
From the early 1980s, several studies conducted in 
hospitals, industries, and pharmacies demonstrated 
that those occupationally involved in the prepara-
tion, transport, administration, and elimination of 
antineoplastic materials were exposed to the risk 
of being contaminated by them (Benhamou et  al., 
1986; Sorsa et  al., 1988; Kiffmeyer et  al., 2013). 
Biological monitoring studies to evaluate the effects 
of antineoplastic agent contamination on healthcare 
personnel have been published for the last 30 years, 
providing evidence of the exposure of healthcare 
professionals to antineoplastic agents. They have 
reviewed the effects caused by acute or prolonged 
exposition (Sorsa et  al., 1988; Sessink et  al., 1994; 
Suspiro and Prista, 2011). Biological monitor-
ing studies, combined with environmental studies, 
could be effective in investigating either the causes 
of contamination or the effects of preventive meas-
ures (Sessink et al., 1997; Turci et al., 2011; Yoshida 
et  al., 2013). Results of environmental studies in 
hospital pharmacies highlighted the presence of 
antineoplastic agent contamination of work sur-
faces (benches, tables, and fridge doors), materials 
(vials, gloves, infusion bags), and floors, but also in 
logistical rooms outside the background clean room 
(Touzin et  al., 2009; Käslin et  al., 2010; Kiffmeyer 
et al., 2013). Based on these results, the professional 
associations and authorities of different countries 
have published guidelines to limit healthcare pro-
fessionals’ exposure to contamination by hazardous 
agents (NIOSH, 2004; Marcel et  al., 2004; ASHP, 
2006).With the objective of confining contamina-
tion, the preparation of antineoplastic treatments 
should be carried out at separate workstations, such 
as in biological safety cabinets (BSC) or isolators. 
It is of utmost importance that an effective post 
drug-preparation cleaning procedure is carried out 
in these workstations in order to limit the accumula-
tion of residual contamination, both chemical and 
microbiological. Several studies have been pub-
lished on different cleaning procedures for surfaces 
contaminated by antineoplastic agents (Roberts 
et al., 2006; Lee et al., 2009; Queruau Lamerie et al., 
2013; Le et  al., 2013). Decontamination protocols 
involving sodium hypochlorite were considered 
effective for a variety of active ingredients, but they 
could damaged cleaned surfaces (need for rins-
ing after use) and were potentially genotoxic (Lee 
et  al., 2009; Sharma et  al., 2013). Hydrogen perox-
ide, whether liquid or vaporized (VHP®), showed 
good decontamination and degradation action on 
5-Fluorouracil, doxorubicin (DOX), and cyclophos-
phamide (CP) (Roberts et  al., 2006). The recently 
published efficacies of cleaning procedures involv-
ing different products highlighted the importance of 
the presence of a surfactant in the cleaning solution 
(Le et al., 2013; Queruau Lamerie et al., 2013). Until 
now, to the best of our knowledge, no clear, practi-
cal recommendations about the decontamination 
procedures to be adopted with antineoplastic agents 
have been available in the literature. A  recent sys-
tematic evaluation of the efficacy of several cleaning 
solutions on 10 antineoplastic agents on different 
surfaces was performed in experimental conditions 
(Queruau Lamerie et al., 2013).
The present work aimed to evaluate the efficacy 
of two cleaning solutions on the decontamination of 
10 antineoplastic agents in a real-world setting. The 
first was an isopropyl alcohol hydroalcoholic solu-
tion (IPA, brand name Klercide®) which has long 
been used for routine BSC cleaning procedures in our 
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centralized cytotoxic preparation unit. The second was 
a sodium dodecyl sulfate (SDS) solution, at a concen-
tration of 10–2 M and with 20% IPA. The latter solution 
was chosen because of the results previously obtained 
from the decontamination of antineoplastic agents on 
stainless steel and glass surfaces (Queruau Lamerie 
et al., 2013). Data were provided from the results of a 
validated global analytical procedure involving a wip-
ing step (Nussbaumer et al., 2012) followed by a liquid 
chromatography mass spectrometry (LC-MS/MS) 
analysis (Nussbaumer et al., 2010, 2012).
M AT E R I A L S  A N D  M E T H O D S
Setting
The Geneva University Hospitals (HUG) central-
ized the preparation of antineoplastic agents in its 
pharmacy in 2000. Two class  III biosafety cabi-
nets (BSC, CDC-D-2GR from Envair, Rossendale, 
England) are installed in a GMP class  C (ISO 
7) background clean room, producing antineoplas-
tic preparations daily. The staff of the pharmacy’s 
cytotoxic unit produces more than 17 000 oncology 
products annually.
Chemicals and reagents
Antineoplastic agents
This study was carried out using the following com-
mercially available antineoplastic preparations: 
Vincristin Teva® (vincristine 1 mg·ml−1, VIN) and 
Methotrexat Teva® (methotrexate 2.5 mg·ml−1, 
MTX), purchased from Teva Pharma AG (Basel, 
Switzerland); Adriblastin® (doxorubicine 2 mg·ml−1, 
DOX), from Pfizer AG (Zurich, Switzerland); 
Epirubicin Actavis Solution® (epirubicin 2 mg·ml−1, 
EPI), from Actavis (Regensdorf, Switzerland); 
Endoxan® (cyclophosphamide reconstituted in 
glucose 5% at 20 mg·ml−1, CP), from Baxter AG 
(Volketswil, Switzerland); Etopophos® (etoposide 
phosphate reconstituted in water at 20 mg·ml−1, 
ETO), from Bristol-Myers Squibb SA (Baar, 
Switzerland); Cytosar® (cytarabine 20 mg·ml−1, 
CYT), from Pfizer AG (Zürich, Switzerland); 
Gemzar® (Gemcitabine, reconstituted in water at 20 
mg·ml−1, GEM), from Eli Lilly (Verbier, Switzerland); 
Irinotecan Fresenius® (irinotecan 20 mg·ml−1, IRI), 
from Fresenius Kabi AG (Stans, Switzerland); and 
Holoxan® (ifosfamide reconstituted in water at 40 
mg·ml−1, IFO), purchased from Ebewe Pharma 
(Cham, Switzerland).
The reconstitutions of Etopophos®, Gemzar®, and 
Holoxan® were carried out with water for injection 
purchased from Bichsel Laboratories (Interlaken, 
Switzerland). Glucose 5% for the reconstitution of 
Endoxan was from Sintetica-Bioren SA (Couvet, 
Switzerland). The internal standard (IS), [13C, 2H3]-
methotrexate, was purchased from Alsachim (Illkirch, 
France).
Other products
The two cleaning solutions were:
1. Commercially available, sterile, hydroalco-
holic solution, Klercide® (IPA: water, 70:30, 
vol:vol; named IPA), from Shield Medicare 
(Farnham, UK), was used directly in a spray 
form;
2. SDS purchased from Sigma-Aldrich 
(Steinhein, Germany) and Klercide® were 
used to produce the detergent cleaning solu-
tion constituted by SDS 10–2 M with 20% of 
Klercide® (vol:vol), and then conditioned in 
a spray bottle.
The LC-MS/MS analysis was performed using the 
following solvents and chemicals: Lichrosolv® HPLC 
grade acetonitrile (ACN) and ultrapure water from 
Merck (Darmstadt, Germany), and formic acid (FA) 
from Biosolve (Valkenswaard, the Netherlands).
Preparation of solutions
All solutions of antineoplastic agents (i.e. drug recon-
stitutions and sample dilutions) were prepared in 
appropriate conditions (i.e. personal protective equip-
ment and BSC) for handling hazardous compounds. 
Aliquots of the IS were prepared with a mixture of ACN 
and water (75:25, vol:vol) at 250 μg·ml−1 and stored at 
−22°C for a maximum of 12 months. Stock solutions 
of IS were diluted on the day of analysis at 50 ng·ml−1 
in ACN 20% with FA 0.1%. A  main stock solution 
containing the 10 antineoplastic agents was prepared 
by diluting each component in water at a concentra-
tion of 20 μg·ml−1. This solution was diluted further to 
obtain five independent stock solutions at 20, 40, 200, 
1000, and 4000 ng·ml−1 in ACN 20% with FA 0.1%. 
For calibration standards (CS), these solutions were 
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diluted using the IS solution at 50 ng·ml−1, to obtain 
five CS at 1, 2, 10, 50, and 200 ng·ml−1. LC-MS/MS 
analyses were performed using three mobile phases: 
ultrapure water (A), ACN (B), and FA 1% (C). The 
needle and the injection loop were washed using 5% 
ACN in water after each injection.
LC-MS/MS analysis
Analyses were carried out using an Accela LC-MS/
MS system (Thermo Fisher Scientific Inc., Waltham, 
MA, USA). The operating system—consisting of a 
quaternary pump equipped with an online degasser, 
an autosampler, and a solvent platform—was coupled 
to a quadrupole (TSQ) Quantum Discovery mass 
spectrometer (MS) (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) equipped with Ion Max electro-
spray ionization (ESI). Separations were carried out on 
a ZOBRAX SB C18 RR 2.1 × 100 mm, 3.5 μm particle 
diameter column (Agilent Technologies, Waldbronn, 
Germany). The chromatographic system coupled to 
the MS operated with Xcalibur® software (Thermo 
Fisher Scientific Inc.). The LC-MS/MS conditions are 
described in detail elsewhere (Nussbaumer et al., 2010).
Wiping and desorption material
The wiping was performed using Protein Saver TM 
903 Card filter paper (Whatman, Dassel, Germany). 
Desorption was performed in 1.5 ml polyethylene 
(PE) safe-lock tubes (Eppendorf AG, Hamburg, 
Germany). The wiping solution was a 20% ACN solu-
tion with 0.1 % FA. The validated wipe sampling pro-
cedure is described in detail elsewhere (Nussbaumer 
et al., 2012). Recoveries of the sampling procedure on 
the different surfaces are presented in Table 1.
BSC decontamination and wiping procedure
Pharmacy technicians are responsible for the manipula-
tion, reconstitution, and production of antineoplastics 
preparations and clean the two BSC in the hospital phar-
macy’s centralized cytotoxic preparation unit two to four 
times a day, at the end of the morning and afternoon work 
sessions. This post-preparation cleaning procedure is per-
formed without opening the BSC, using a sterile solu-
tion of IPA and TX612 TechniCloth wipes (TexWipe, 
Kernersville, NC, USA) on all inside surfaces. Gloves are 
changed after the post-preparation cleaning procedure.
Once a week, the two BSC are opened and cleaned 
in depth by trained cleaning technicians in charge for 
the cleaning and preparation of BSC before the work 
sessions. This study focused on this weekly cleaning 
procedure, in order to evaluate the efficacy in routine 
conditions of a SDS solution in comparison with the 
usual IPA solution. Both solutions were used with an 
identical cleaning protocol, as follows: (i) the front 
panel was opened; (ii) all materials inside the BSC were 
taken out [e.g. scale, stainless steel work bench, gravi-
metric control (CATO®) hardware]; (iii) the clean-
ing solution (see after) was sprayed on all the interior 
surfaces (also inside the airlock box, and the insides of 
sleeves) and wiped using TX612 TechniCloth wipes; 
(iv) materials taken out were also sprayed and wiped 
with the same solution; (v) the exterior surfaces (also 
outside the airlock box and the outsides of sleeves) 
were cleaned as described previously; (vi) all the 
cleaned objects were replaced in the BSC; and (vii) 
the BSC was closed and air was circulated for 15 min 
before a new work session could start. In total, surfaces 
were wiped between 13 and 23 times a week in BSC 1 
and between 11 and 21 times a week in BSC 2, depend-
ing on the quantity of chemotherapies produced.
In order to compare the efficacy of the two solu-
tions tested, a specific weekly cleaning procedure was 
applied to each BSC:
1. For BSC 1, a three-step cleaning procedure 
was applied to surfaces and materials: (i) 
surfactant cleaning solution (SDS10–2 M 
+ 20% IPA); (ii) sterile water (to rinse 
residues of SDS); and (iii) IPA (to guarantee 
microbiological decontamination). Each step 
was followed by a wiping step for all surfaces.
2. For BSC 2, the usual one-step procedure 
was applied using IPA on all surfaces and 
materials.
The two BSC were decontaminated on the same days 
by the same cleaning technician, following instruc-
tions to frequently change the wipes used for the 
cleaning procedure. Around 12–15 wipes were used 
for the entire cleaning procedure for one BSC. Time 
required to complete the cleaning procedure in BSC1 
was 1 h. BSC 2 cleaning procedure took 30 min to be 
completed. Time required completing the cleaning 
procedure were operator-dependent.
In order to compare the efficacy of the two cleaning 
procedures, seven spots inside the BSC (Fig.  1) were 
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wiped for sampling, both before and after the cleaning 
procedure described here. Wiping spots were: 100 cm2 
of sleeves (polypropylene), 100 cm2 of the left side of 
the work bench (stainless steel), the scale plate (stain-
less steel), the gravimetric control (CATO®) hardware 
(mouse in BSC 1, keyboard in BSC 2, plastic), and 
airlock handles (polyester).Wiping was performed 
following a validated procedure (Nussbaumer et  al., 
2012). After wiping, the samples were placed in a PE 
safe-lock (Eppendorf AG, Hamburg, Germany) and 
stored at −22°C until LC-MS/MS analysis. Sampling 
was performed once a week for the first 3 weeks (W) of 
the study, then every 4 or 5 weeks over nearly a year (49 
weeks in total). During this entire period, the two BSC 
were cleaned weekly, as described earlier; in total, meas-
urement of contamination was performed 14 times.
Decontamination overview and efficacy calculation
Total contamination and impact of the introduced 
quantities of antineoplastics
For each wiping spot, the cumulative contamination 
of the 10 antineoplastic agents (GEM, CYT, CP, VIN, 
MTX, DOX, EPI, IFO, ETO, and IRI) was expressed 
in terms of total quantity (= Q in ng). Mean of Q(Q ) 
across the 14 contamination measurements was calcu-
lated. Total contamination level was expressed as the 
sum of Q (ΣQ) of all wiping samples during a wiping 
Table 1. Quantitative performance of the wiping method for the 10 antineoplastic drugs on different 
surfaces, adapted from (Nussbaumer et al., 2012).
Surface material Stainless steel Polypropylene Computer mouse
CYT Recovery (%) 81 79 69
Intermediate precision (%) 8.3 7.8 8.8
GEM Recovery (%) 82 79 81
Intermediate precision (%) 9.5 8.8 6.4
MTX Recovery (%) 63 85 64
Intermediate precision (%) 9.8 5.1 9.8
ETO Recovery (%) 45 82 81
Intermediate precision (%) 7.8 8.2 22.6
IFO Recovery (%) 82 91 98
Intermediate precision (%) 10.4 8.2 24.8
CP Recovery (%) 86 94 77
Intermediate precision (%) 10.8 4.8 20.4
IRI Recovery (%) 57 84 45
Intermediate precision (%) 11.8 11.9 12.0
DOX Recovery (%) 46 54 35
Intermediate precision (%) 5.1 6.1 12.2
VIN Recovery (%) 46 58 19
Intermediate precision (%) 5.2 6.2 11.1
EPI Recovery (%) 50 55 22
Intermediate precision (%) 12.0 11.9 12.3
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campaign for each BSC. The relationship between the 
quantity of the 10 antineoplastic agents introduced 
into each BSC during the week before the cleaning 
procedure and the ΣQbefore cleaning procedure was studied 
using a linear regression. This was in order to evaluate 
whether the quantity of antineoplastic agents handled 
in each BSC influenced ΣQ.
Decontamination efficacy
The contamination overview was expressed by ΣQ at 
the time of wiping (W1, W2,..., W49).The difference 
between ΣQbefore cleaning procedure and ΣQafter cleaning procedure was 
expressed by ΔQ. Positive and negative values of ΔQ 
were observed. Efficacy (EffQ) was calculated from ΣQ 
values of all seven spots, for the two BSC at the time of 
wiping, using Equation 1.
 Eff
Q
QQ
after cleaning procedure
before cleaning procedu
= −
∑
∑1 re



 %  (1)
The average of EffQ was calculated. Results of EffQ < 
0 were considerate as 0% (no decontamination had 
occurred).
Analysis of the contamination on the wiping areas for 
the 10 selected antineoplastic agents
Contamination by each separate cytotoxic agent was 
expressed in terms of quantity (= q in ng). The dis-
tribution of the contaminations in each BSC was cal-
culated using the mean values of q(q) of all wiping 
samples from a selected spot. Means were calculated 
to evaluate the general trends in the decontamination 
procedures and to highlight any accidental contamina-
tion during the study.
The decontamination efficacy (Effq) of the two 
cleaning solutions on the 10 cytostatic agents was cal-
culated from the q values of all seven spots for the two 
BSC at the time of wiping using, Equation 2.
 
Eff of selected 
antineoplastic agents
qq after cleaning pr
= −1 ocedure
before cleaning procedureq



 %  
(2)
Efficacy of the cleaning solutions was evaluated by cal-
culating the mean of all Effq of a selected antineoplas-
tic agent according to the cleaning solution employed 
during the cleaning procedure. When Σqafter cleaning procedure 
was higher Σqbefore cleaning procedure a negative Effq result had 
occurred. To evaluate the efficacy of the cleaning solution 
on antineoplastic agents, results of Effq < 0 were consid-
ered as 0%, as no decontamination had occurred. Fisher–
Student tests (α < 0.05) were carried out to compare the 
average efficacy of the two cleaning solutions, and to 
evaluate whether a difference of efficacy on antineoplas-
tic agents existed between the two cleaning solutions.
R E S U LT S
During this study, 390 wiping samples (195 for BSC 1 
(SDS + IPA) and 195 for BSC 2 (IPA)) were collected.
Total contamination and impact of the introduced 
quantities of antineoplastic agents
Q BSC 1 was 3557.6 ± 2700.5 ng for Q before  and 
402.3 ± 333.4 ng for Q after. The Q BSC 2  levels 
Figure 1 Representation of a biosafety cabinet with seven sampling spots 
highlighted: (a) left and right sleeves; (b) work bench; (c) scale plate; (d) CATO 
mouse or keyboard; (e) left and right airlock handles. 
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detected were 2997.1 ± 2239.4 ng for Q before  and 
3168.2 ± 3261.4 ng for Q after. Results showed higher 
values of Q beforecleaning procedure in BSC 1 than in BSC 
2.  No linear relationship was evident between the 
detected Q and the total quantity of the 10 antineo-
plastic agents treated in the BSC in the week before 
the analyses (R2 < 0.06 for both BSC) (Fig. 2).
Decontamination efficacy
EffQ for each BSC was calculated using Equation 1, in 
order to evaluate the general efficacy of the cleaning 
solutions on the 10 selected antineoplastic agents; this 
is represented by the histograms in Fig.  3. For BSC 
1 (SDS), an average EffQ value of 82% ± 6% [relative 
standard deviation (RSD) 13%] was observed. At 
each wiping campaign, a positive ΔQ was measured, 
indicating a decrease in the contamination level after a 
cleaning procedure. An average EffQ value of 49 ± 11% 
(RSD 29%) was obtained for BSC 2 (IPA), and three 
samples (W1, W2, and W44) were found to present 
negative values of ΔQ. 
Analysis of the contamination of wiping areas for the 10 
selected antineoplastic agents
Mean values of q (q), for the 10 cytostatic agents, were 
plotted according to the wiping areas. Results of the 
contamination distribution are shown in Table  2. For 
both BSC, the most contaminated areas were sleeves 
and airlock handles. On two occasions (during weeks 1 
and 2), in the BSC 2 airlock, handles were contaminated 
with high qCYT (over 1200 ng) both before and after the 
cleaning procedure. In both BSC, values of qCP, qIFO, 
qGEM, and qCYT were higher than the q  of the other cyto-
static agents. Efficacy of the two cleaning solutions used 
during the cleaning procedure for the 10antineoplastic 
agents was expressed in terms of means values of Effq 
(Fig. 4). Efficacy was calculated as an evaluation of the 
percentage of antineoplastic agents washed away during 
the cleaning procedure. A high value of Effq meant that 
the contamination had been reduced during the clean-
ing procedure. The efficacy of the SDS solution was 
higher than that of IPA on eight of the 10antineoplas-
tic agents (CYT, GEM, MTX, ETO, IFO, CP, IRI, and 
DOX). SDS solution was almost 20% more effective 
than IPA on almost all antineoplastic agents. IPA was 
more effective on VIN and EPI, but both cleaning solu-
tions showed efficacies lower than 20%. As shown in 
Fig. 4, significant differences in the efficacy of the clean-
ing solutions were only observed for CYT, GEM, and 
CP (P < 0.05, Fisher–Student test).
D I S C U S S I O N
This study aimed to compare the efficacy of two clean-
ing solutions for the chemical decontamination of two 
class III BSC. These BSC were used daily to produce 
chemotherapies in the centralized cytotoxic prepara-
tion unit in a hospital pharmacy. Over the course of 
a year, each of BSC was cleaned with a different solu-
tion: a solution of 10–2 M of SDS containing 20% 
IPA (BSC 1), and a solution of IPA (BSC 2). SDS 
solution was chosen based on results of a previous 
experimental study (Queruau Lamerie et  al., 2013), 
Figure 2 Relationship between the quantities of the 10 antineoplastic agents 
introduced in the BSC for the chemotherapy preparations and the quantities 
detected (Q) before the cleaning procedure. BSC 1) y = 5.9948 x + 33218, 
R2 = 0.059; BSC 2) y = −0.3824x + 39772, R2 = 0.0003. 
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while IPA is the disinfectant conventionally used in 
routine microbiological cleaning of BSC in numerous 
pharmacy hospitals. Throughout the duration of the 
study, contaminations by antineoplastic agents were 
detected in both BSC both before and after the clean-
ing procedures.
Total contamination and the impact of introduced 
quantities of antineoplastic agents
Higher total quantities of antineoplastics were 
detected for Q BSC 1 than for Q BSC 2 . Several factors, 
including the quantity of introduced antineoplastic 
agents, were investigated to explain this difference, and 
Figure 3 Contamination rate over view in terms of ΣQ of all antineoplastics and efficacy histograms 
are plotted according to the wiping campaigns.
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Table 2. Mean q values of antineoplastic tested, at wiping spot. Values in bold denote samples 
collected before the cleaning procedure and values in brackets denote samples collected after the 
cleaning procedure.
Sleeve L Sleeve R Airlocks 
handles L
Airlocks 
handles R
CATO® mouse Working 
bench
Scale plate
BSC 1 (SDS)
 CYT 49.7  
(1.9)
108.2  
(11.2)
18.5  
(3.5)
40.1  
(5.0)
27.6  
(1.0)
8.9  
(1.0)
9.8  
(1.2)
 GEM 115.3  
(1.3)
104.8  
(2.2)
64.2  
(6.9)
43.7  
(5.0)
19.7  
(2.2)
18.1  
(20.9)
37.9  
(0.9)
 MTX 110.4  
(0.9)
30.0  
(1.7)
6.0  
(0.6)
7.4  
(2.1)
8.0  
(3.3)
16.7  
(0.7)
386.6  
(0.6)
 ETO 9.9  
(0.4)
64.9  
(0.00)
2.0  
(0.0)
0.7  
(1.3)
5.8  
(0.1)
0.2  
(0.2)
0.2  
(0.0)
 IFO 132.4  
(77.9)
675.0  
(30.2)
643.2  
(78.0)
257.3  
(28.6)
23.3  
(6.6)
6.7  
(2.0)
5.3  
(0.9)
 CP 19.3  
(4.2)
51.8  
(10.4)
11.2  
(3.5)
29.3  
(2.7)
131.9  
(15.5)
4.0 ( 
1.8)
26.4  
(0.9)
 IRI 1.7  
(0.2)
0.4  
(0.2)
1.9  
(0.3)
1.4  
(0.3)
0.6  
(0.3)
1.7  
(1.7)
0.7  
(0.1)
 DOX 0.3  
(0.1)
0.2  
(0.4)
1.0  
(0.4)
0.6 ( 
0.4)
0.2  
(0.2)
0.4  
(0.3)
0.4  
(0.2)
 VIN 26.0  
(4.9)
23.3  
(5.8)
27.9  
(5.5)
16.7  
(9.4)
15.8  
(11.3)
13.8  
(0.2)
22.7  
(3.0)
 EPI 22.7  
(1.6)
10.9  
(2.8)
18.7  
(1.6)
12.3  
(4.2)
15.2  
(5.5)
8.1  
(0.6)
13.4 
(1.1)
BSC 2 (IPA)
 CYT 329.8  
(8.7)
189.6  
(52.3)
1613.4 
(1464.4)
108.6  
(1292.7)
8.8 ( 
5.4)
5.4  
(5.8)
23.4  
(4.9)
 GEM 98.8  
(13.4)
104.5  
(18.3)
21.5  
(13.7)
20.0  
(11.8)
39.6  
(8.1)
7.8  
(10.6)
18.5  
(4.0)
 MTX 12.9  
(2.4)
10.3  
(2.0)
6.1  
(1.2)
2.7  
(0.8)
1.0  
(0.5)
2.7  “ 
(6.1)
15.2  
(0.5)
 ETO 0.0  
(0.0)
0.0  
(83.6)
0.4  
(0.1)
0.0  
(0.0)
0.6  
(0.0)
0.0  
(0.0)
0.7  
(0.0)
 IFO 29.4  
(12.5)
24.8  
(9.7)
97.2 ( 
10.7)
13.9  
(23.1)
4.1  
(2.1)
3.5  
(3.8)
3.5  
(1.2)
 CP 13.2  
(4.3)
19.2  
(4.5)
13.7  
(5.1)
14.0  
(5.2)
14.6  
(2.7)
2.0  
(0.8)
4.2  
(1.1)
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no significant relationship was observed. Literature 
describes several factors which can have an impact 
on contamination levels—such as operators training, 
work practices, materials, and facilities (Marcel et al., 
2004; Käslin et al., 2010; Le et al., 2013)—these were 
beyond the scope of this study.
Independent guidelines have suggested a reference 
value of 1 ng cm−2 (Käslin et al., 2010), based on the 
experimental 90th percentile of the contamination 
load detected during the MEWIP study (Kiffmeyer 
et al., 2013). In this study, 10 antineoplastic agents are 
detected in seven areas, each of about 100 cm2, which 
gave a total contamination reference value of about 
7000 ng. Target contamination levels in the MEWIP 
study were 0.1 ng cm−2, corresponding roughly to a 
700 ng contamination level in this study. Q  values 
before the cleaning procedure ranged between 7000 
and 700 ng. Q BSC 1 values were lower than 700 ng 
after the cleaning procedure whereas Q BSC 2  values 
were always higher than this target value. These results 
suggest that the SDS solution (BSC 1)  had indeed 
decreased contamination to acceptable levels (700 ng 
in our case), but that IPA had not (BSC 2). Moreover, 
some Q BSC 2 values for after the cleaning procedure 
were higher than Q BSC 2 values before it, suggesting 
either that IPA was less effective than the SDS solution 
or that a dispersion of antineoplastic agents occurred 
during the cleaning procedure.
Figure 4 Efficacy of cleaning solutions on 10 antineoplastic agents in BSC 1 and BSC 2 
during the study, with P value results of Fisher–Student test in brackets.
Sleeve L Sleeve R Airlocks 
handles L
Airlocks 
handles R
CATO® mouse Working 
bench
Scale plate
 IRI 4.9  
(5.2)
3.9  
(3.0)
23.7  
(1.4)
19.2  
(3.8)
9.1  
(1.1)
3.1  
(0.4)
4.0  
(0.5)
 DOX 0.3  
(0.3)
0.5  
(0.3)
0.4  
(0.5)
0.5  
(0.4)
0.3  
(0.4)
0.4  
(0.3)
0.2 (
0.4)
 VIN 13.7  
(0.2)
0.1  
(0.2)
0.6  
(6.2)
0.2  
(7.5)
0.1  
(0.2)
0.3 (9.5) 0.7  
(9.9)
 EPI 13.4  
(0.5)
0.5  
(0.5)
0.4  
(3.6)
0.5  
(5.7)
0.4  
(4.0)
0.5  
(1.8)
0.3  
(2.0)
Table 2. Continued
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Decontamination efficacy
According to experimental conditions results show-
ing a better decontamination efficacy for a SDS 10–2 M 
solution with 20% IPA than for an IPA solution alone 
(Queruau Lamerie et al., 2013), a larger ΔQ could have 
been expected in the BSC cleaned using the SDS solu-
tion (BSC 1). A  decrease in contamination level was 
indeed observed for all the BSC 1 samples after a clean-
ing procedure (ΔQ always positive). During the W1, W2, 
and W44 wiping campaigns in BSC 2, however, ΔQ val-
ues were negative. This was probably due to a dispersion 
of antineoplastic agents during the IPA solution cleaning 
procedure in that BSC. Similar effects were discussed 
in another study on the efficacy of cleaning solutions, 
which showed a higher dispersion potential for alcoholic 
solutions than for detergent solutions (Le et al., 2013). It 
should be noted that traces of contamination remained 
after the cleaning procedures whichever solution was 
used. This residual contamination was also observed 
in other studies investigating the efficacy of cleaning 
solutions based on a desorption phenomenon (Le 
et al., 2013; Queruau Lamerie et al., 2013).Desorption-
type cleaning procedures are not able to completely 
eliminate contamination. Better efficacy was obtained 
with decontamination protocols involving destruc-
tive agents such as sodium hypochlorite or hydrogen 
peroxide (Castegnaro et  al., 1997; Hansel et  al., 1997; 
Roberts et  al., 2006). However, due to several major 
drawbacks, including surface corrosion (ISOPP, 2007) 
and the production, by oxidation, of mutagenic resi-
dues (Castegnaro et al., 1985; Barek et al., 1998), these 
products are not suitable for routine use in BSC cleaning 
procedures. The present study’s results for cumulative 
contamination levels demonstrated that even if the SDS 
solution were more effective than IPA, both experimen-
tal and routine conditions, the total decontamination of 
a BSC cannot be reached. The cleaning product itself is 
only one of several factors—including cleaning proce-
dures, pharmacy technicians awareness, and training of 
cleaning technicians—which need to be evaluated and 
optimized in order to decrease contamination levels in 
BSC (Roberts et al., 2006; Käslin et al., 2010; Le et al., 
2013).The effect of the number of mechanical clean-
ing was neglected between the two methods because 
no significant difference in the efficiency was observed 
between a one-step procedure and a three-step cleaning 
procedure using IPA only (Table  3). Indeed to assess 
whether the mechanical action affects the efficacy of the 
cleaning procedure, BSC 2 was once cleaned three times 
with IPA (W13). EffQ value of a three steps cleaning pro-
cedure (57%) was included in the confidence interval 
(49% ± 16%), calculated from the EffQ values of one-
step cleaning procedures.
Analysis of the contamination by wiping area for the 
10 selected antineoplastic agents
The higher contamination levels detected on sleeves 
and airlock handles were probably due to a high fre-
quency of contact with gloves, as observed elsewhere 
(Sessink et  al., 1992; Chu et  al., 2012). Moreover, 
sleeves are voluminous and relatively difficult to clean 
Table 3. Mean Eff
Q
 values of BSC 2 (IPA) 
according to the number of cleaning steps. 
Confidence interval was included from 33 to 
65%.
Eff
Q
 BSC 2 (IPA)
Step count 1 3
W1 0%
W2 0%
W3 91%
W10 51%
W13 57%
W17 76%
W21 53%
W26 90%
W30 54%
W35 59%
W39 65%
W44 0%
W47 27%
W49 67%
n 13
Mean 49%
SD 31%
CI 49 ± 16%
Decontamination efficacy of two cleaning solutions • 905
by the pharmacy technicians themselves during the 
post-preparation cleaning procedure, leading to only 
a partial elimination, or a dispersion, of contamina-
tion. Sleeves are also permanently close to vials of 
products in the preparation area, increasing the risk 
of contamination by dispersion of the contaminant 
present on the outside of vials (Favier et  al., 2003; 
Connor et  al., 2005; Fleury-Souverain et  al., 2014) 
or by drops, spills, or aerosols generated during drug 
manipulation(Vyas et al., 2013).Dispersion might also 
occur during the cleaning procedure, as observed in 
BSC 2, when airlock handles were contaminated with 
elevated qCYT both before and after the cleaning pro-
cedure. Lower contamination levels were observed 
on the scale plate, CATO® hardware and the work 
bench. Indeed, only materials such as syringes or infu-
sion bags touch the scale plate. Lower contamination 
levels on work benches could be explained by the use 
of a disposable preparation mats, placed in the center 
of the preparation area, which protect the stainless 
steel surfaces: when preparation sessions are over (or 
if visible contamination is observed), the disposable 
preparation mat is carefully folded, discarded into a 
waste bag, sealed, and taken out using the left airlock 
(and replaced) to be destroyed. No sampling was per-
formed on the disposable mats. The use of preventive 
protective measures (like the work bench mat) could 
decrease the risk of contamination by antineoplastic 
agents. In order to limit cross-contamination, a glove 
changes could occur between preparations when a 
different antineoplastic agent is used (Mason et  al., 
2003; Fleury-Souverain et al., 2014). To prevent spill-
age or drops during the manipulation of antineoplastic 
agents, the HUG pharmacy uses vented needles con-
taining a hydrophobic filter or a chemo-dispensing 
pin. Although these devices improve safety during 
the chemotherapy preparation session (Siderov et al., 
2010; Favier et  al., 2012) and are useful for reduc-
ing contamination levels, their use does not appear 
to have been sufficient to eliminate the risks of spills 
or drops when the syringe is disconnected from the 
device during preparation sessions(Guillemette et al., 
2014). In both BSC, contamination values for qCP, 
qIFO, qGEM, and qCYT were higher than the q  for other 
cytostatic agents. The higher contamination levels for 
these four antineoplastic agents (CP, IFO, GEM, and 
CYT)was probably due to their higher therapeutic 
doses and the risk of spills or drops associated with 
the reconstitution step of the freeze-dried drugs (IFO 
and GEM). SDS solution was more effective than IPA 
on hydrophilic molecules (CYT, GEM, MTX, ETO, 
IFO, and CP), but also on two hydrophobic molecules 
(IRI and DOX), due to the presence of an anionic sur-
factant promoting the formation of micelles, as previ-
ously demonstrated elsewhere(Le et al. 2013; Queruau 
Lamerie et al. 2013). During this study, results for the 
efficacy of SDS showed a greater potential for the 
decontamination of eight antineoplastic agents. Using 
SDS solution instead of IPA solution during the clean-
ing procedure reached a statistically significant bet-
ter decontamination on three of these antineoplastic 
agents: CYT, GEM, and CP. The results obtained in 
the present routine use study were sometimes differ-
ent from experimental conditions studies; this could 
be explained by the fact that contamination levels of 
the 10 antineoplastic agents were unpredictable com-
pared to standardized simulated contamination. This 
difference had an impact on efficacy (i.e. high levels of 
contamination were more difficult to clean up), lead-
ing to higher residual contamination after the cleaning 
procedure. Other potential sources of differences con-
cerned the contact time which antineoplastic agents 
had with the air, their exposition to light. Moreover 
heterogeneity of contaminated surfaces (stainless steel, 
polypropylene, polyester, and plastic) could explain 
the differences between the experimental and routine 
conditions results of the efficiency on CYT, GEM, or 
CP. The inherent variability of different cleaning tech-
nicians’ ways of applying procedures could also have 
had an impact on the efficacy of decontamination. 
Before the study, the cleaning method to be applied 
was decided upon with reference to the routine pro-
cedure. Although the sequence for this procedure was 
followed by all the cleaning technicians and did not 
change throughout the study, some differences, such 
as the quantity of cleaning product sprayed or the 
wiping path, were observed. These differences were 
dependent on the individual cleaning technicians and 
could be reduced by the highly detailed training of 
these personnel in BSC cleaning procedures (Käslin 
et al., 2010; Le et al., 2013).
C O N C L U S I O N S
This study evaluated the efficacy of two cleaning solu-
tions for the chemical decontamination of 10 antineo-
plastic agents (GEM, CYT, CP, VIN, MTX, DOX, 
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EPI, IFO, ETO, and IRI) on the surfaces of two BSCs 
in a real-world context. The efficacy of a solution con-
taining a surfactant agent—the SDS solution—was 
shown to be higher than the efficacy of the IPA solu-
tion alone, thus confirming experimental conditions 
studies. Neither cleaning solution was able to totally 
remove the contamination, but the efficacy of the 
cleaning solution containing a surfactant was suffi-
cient to reduce the contamination of each individual 
antineoplastic agent to under a level corresponding to 
the 0.1 ng cm−2, the acceptable limit proposed by the 
MEWIP study (Kiffmeyer et  al., 2013).The present 
study’s results also suggested that the decontamina-
tion of BSC depends on such important factors as 
the cleaning products used, cleaning procedures, the 
awareness of pharmacy technicians, and the training 
of cleaning technicians. Measures such as standardized 
cleaning protocols and regular training of the clean-
ing technicians must be undertaken in order to make 
cleaning procedures more effective. Additional meas-
ures, such as the use of a second pair of gloves, the 
decontamination of external vial surfaces or the use of 
closed system drug transfer devices, should be consid-
ered in an effort to reduce initial contamination. The 
cleaning procedure using the SDS solution could be 
easily transferred and applied to other contaminated 
surfaces presents in pharmacy or health care units 
working with antineoplastic agents. However, future 
studies are required to carry out a detailed investiga-
tion of glove contamination levels, e.g. to look at the 
impact of standardized cleaning protocols on cleaning 
efficacy and to analyze the decontamination of further 
antineoplastic agents.
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